Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial Demonstrating Glycemic Control Comparable to Humalog(R)

Biodel's BIOD-123 Achieves Primary Endpoint in Phase 2 Clinical Trial
Demonstrating Glycemic Control Comparable to Humalog(R)

Conference Call and Webcast Will be Held Monday, September 9th, at 8:00 a.m.

DANBURY, Conn., Sept. 8, 2013 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD)
today announced preliminary results from Study 3-201, a Phase 2 clinical study
of BIOD-123, an investigational ultra-rapid-acting mealtime insulin, in
patients with type 1 diabetes. BIOD-123 achieved the primary endpoint of
non-inferiority for HbA1c relative to insulin lispro, a widely prescribed
rapid acting mealtime insulin analog marketed as Humalog^®.


Compared to Humalog^®, BIOD-123 demonstrated:

  *Achievement of primary efficacy endpoint; demonstration of non-inferiority
    in change from baseline HbA1c
  *Comparable weight gain, mean hypoglycemia event rates and postprandial
    glucose excursions over the entire treatment period with some notable
    trends in favor of BIOD-123 in weight gain during the stable dosing
    period, median hypoglycemia event rates and postprandial glucose
    excursions to a liquid meal challenge test
  *Comparable safety and adverse event profiles with the exception of an
    increased frequency of injection site pain associated with BIOD-123 which
    appears to be clinically minor, was short-lived and did not result in
    patient dropouts

Dr. Alan Krasner, chief medical officer of Biodel, stated: "BIOD-123 has
passed the first and most critical test—showing that HbA1c non-inferiority can
be achieved in a multi-dose outpatient setting. This study provides a rich
database which will be used to explore how two insulins with distinct
pharmacodynamic profiles can influence a number of important clinical
outcomes. Continued analysis of this database will be invaluable in our
development of BIOD-123 and other meal-time insulin candidates."

Dr. Errol De Souza, president and chief executive officer of Biodel, stated:
"The establishment of non-inferiority in HbA1c of BIOD-123 versus Humalog^® in
this study gives us a high level of confidence that BIOD-123 could achieve
this primary endpoint for FDA approval in larger pivotal studies. We look
forward to completing the full analysis of the results, sharing the data with
experts and potential partners to obtain feedback and preparing for an end of
Phase 2 meeting with the FDA to define the path forward."

About Study 3-201


Study 3-201 is a Phase 2, open-label, parallel group study conducted at 32
centers in the U.S. In the trial, 132 patients with type 1 diabetes and HbA1c
levels between 6.5-8.5% were randomized to receive either BIOD-123 or
Humalog^® to use as their mealtime insulin during an 18-week treatment period.
Both arms of the study used insulin glargine, sold as Lantus^®, as the basal
insulin. Following randomization, subjects entered a 6-week dose titration
period during which basal insulin and then prandial insulin doses were to be
titrated in order to reach standard American Diabetes Association (ADA)
recommended pre-prandial glucose targets. Upon completion of the titration
period, subjects entered a "relative stable dosing period" for an additional
12 weeks.

Secondary endpoints include hypoglycemic events measured and analyzed
according to ADA Workshop recommendations, weight recorded at multiple time
points and postprandial glucose excursions measured in multiple ways including
a liquid meal challenge test, 10-point glucose profiles, continuous glucose
monitoring profiles and routine self-monitoring of blood glucose (SMBG) levels
throughout the study. The study was powered to demonstrate non-inferiority of
HbA1c. As is typical with a Phase 2 Study, the goal with respect to the
secondary measures was to look for initial trends that would assist in the
design of future studies. Endpoints were analyzed primarily using the day of
randomization as baseline. These analyses involve data from the entire 18-week
treatment period, including the initial 6-week titration phase. Secondary
analyses were also performed using Week 6 (the end of the dose titration
period) values as baseline. These results assess changes during the 3 month
stable dosing period.


Sixty six (66) subjects were randomized into each arm of the study. A central
randomization process was utilized. At baseline, mean HbA1c was balanced
between treatment groups: 7.36% in the BIOD-123 group and 7.33% in the
Humalog^® group. Several between-group imbalances were noted in the baseline
characteristics of the randomized subjects. The mean age in the BIOD-123 group
was 48.8 years compared to 41.3 years in the Humalog^® group. The mean
duration of diabetes was 25.8 years in the BIOD-123 group compared to 20.5
years in the Humalog^® group. 50.8% of the subjects in the BIOD-123 group were
female compared to 28.8% in the Humalog^® group. The mean weight in the
BIOD-123 group was 78.6 kg compared to 84.3 kg in the Humalog^® group, likely
related to the difference in gender make-up between the two groups. Body mass
index (BMI), however, was more closely balanced at baseline: 26.8 kg/m^2 in
the BIOD-123 group and 27.0 kg/m^2 in the Humalog^® group. Subjects randomized
to the BIOD-123 arm were treated at the beginning of the study with an average
of 52.4 units (0.64 units/kg) of insulin, and those randomized to Humalog^®
were treated with 60.2 units (0.71 units/kg) of insulin.

The randomization was performed properly and the observed baseline imbalances
occurred by chance in this Phase 2 study with limited sample size. The
baseline imbalances do not affect the conclusion of non-inferiority of HbA1c.
Some gender-based differences in weight change were observed. The effect of
gender and possible dose imbalances on other secondary variables are under


The primary objective of the study was to demonstrate non-inferiority in
change from baseline HbA1c, defined as the upper bound of the 95% confidence
interval around change from baseline HbA1c< 0.40%. The mean HbA1c change from
baseline in the BIOD-123 group was -0.08 ± 0.064% and -0.25 ± 0.063% in the
Humalog^® group. The 95% confidence interval (-0.01, 0.35) of the between
group difference in change from baseline HbA1c did not exceed the
pre-determined threshold of 0.40%, thereby establishing non-inferiority. HbA1c
change during the stable dosing period was similar in both treatment arms.
During this period, the mean change in HbA1c in the BIOD-123 group was -0.01%
and in the Humalog^® group was +0.02%.

Hypoglycemia frequencies and mean event rates were not statistically
significantly different between groups. However, in the most frequent forms of
hypoglycemia reported, median event rates appear to be lower in the BIOD-123
group compared to Humalog^®. This observation requires further investigation.

Baseline weights were substantially different between groups, however, the
change from baseline in weight was not significantly different; both groups
gained on average 1.0 kg over the course of the study. During the 6-week
titration period, patients in the BIOD-123 group gained an average of 0.94 ±
0.31 kg, and patients in the Humalog^® group gained an average of 0.43 ± 0.35
kg. In contrast, during the subsequent stable dosing period of 12 weeks,
patients in the BIOD-123 group gained an average of 0.10 kg compared to 0.60
kg in the Humalog^® group. This beneficial weight trend in favor of BIOD-123
during the stable dosing period was observed in both genders, yet was more
pronounced in females in which a small weight loss was observed.

Postprandial glucose was measured using multiple methods, generating a dataset
of more than 1.5 million data points, many of which are still being analyzed.
Postprandial glucose excursions are defined as the change in glucose
concentration from before to after a meal. In the liquid meal challenge test,
the average baseline glucose values of 177.3 mg/dl were higher in the BIOD-123
group compared to 148.3 mg/dl in the Humalog^® group. The maximal postprandial
glucose excursion of 71.8 mg/dl was significantly lower in the BIOD-123 group
compared the 92.6 mg/dl maximal glucose excursion in the Humalog^® group; this
difference was significant at p=0.034. Additional statistical analysis
indicates that this significant difference in excursion is not due to the
differences in baseline glucose or gender.

Initial overall analyses show mostly no differences in 10-point SMBG or
continuous glucose monitoring profiles. Some time points show lower
postprandial glucose values in the Humalog^® arm. Additional analyses of
within-patient glucose excursions are pending.

Overall, the adverse event profile between treatment groups appears to be
balanced with the exception of injection site pain. Drop-out rates in the two
arms of the study were similar. No patients in either the BIOD-123 or
Humalog^® arm reported an incidence of severe pain or dropped out of the study
because of injection site pain. One patient (1.5%) in the BIOD-123 arm
reported a single incidence of moderate pain, compared to none in the
Humalog^® arm. Nine patients (13.8%) in the BIOD-123 group reported at least
one episode of mild injection site pain during the study compared to 1 patient
(1.5%) in the Humalog^® group. Six out of 10 patients reporting discomfort
with BIOD-123 had complete resolution during the course of the study while
continuing study drug. It was noted that about half of the patients in the
study reporting injection site pain were from 2 out of 32 investigative sites,
with patients from 25 out of 32 sites reporting no injection site pain.
Injection site pain associated with BIOD-123 was not a medically important
safety issue and was greatly improved relative to that associated with

Conference Call and Webcast Information

Biodel's senior management will host a conference call on Monday September 9,
2013 beginning at 8:00 a.m. Eastern Daylight Time to discuss these results. A
live audio and visual webcast of the conference call will be available to
investors, members of the news media and the general public by going to To access audio
only by telephone, dial +1 (877) 303-8025 (United States) or +1 (760) 536-5162
(international). An archived version of the webcast will be available on
Biodel's website. Interested parties may also access an audio replay by
dialing (855) 859-2056 (US) or (404) 537-3406 (International) and entering
conference ID number 53679974.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the
development and commercialization of innovative treatments for diabetes that
may be safer, more effective and more convenient for patients. Biodel's
product candidates are developed by applying proprietary technologies to
existing drugs in order to improve their therapeutic profiles. More
information about Biodel is available at 

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include statements about future activities related to the clinical
development plans for the company's drug candidates, including the potential
timing, design and outcomes of clinical trials; and the company's ability to
develop and commercialize product candidates. Forward-looking statements
represent our management's judgment regarding future events. All statements,
other than statements of historical facts, including statements regarding our
strategy, future operations, future clinical trial results, future financial
position, future revenues, projected costs, prospects, plans and objectives of
management are forward-looking statements. The words "anticipates,"
"believes," "could," "estimates," "expects," "intends," "may," "plans,"
"potential," "predicts," "projects," "should," "will," "would" and similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. The company's
forward-looking statements are subject to a number of known and unknown risks
and uncertainties that could cause actual results, performance or achievements
to differ materially from those described or implied in the forward-looking
statements, including, but not limited to, the success of our product
candidates, particularly our proprietary formulations of injectable insulin
that are designed to be absorbed more rapidly than the "rapid-acting" mealtime
insulin analogs presently used to treat patients with type 1 and type 2
diabetes and our glucagon presentation that is intended to treat patients
experiencing severe hypoglycemia; our ability to conduct pivotal clinical
trials, other tests or analyses required by the U.S. Food and Drug
Administration, or FDA, to secure approval to commercialize a proprietary
formulation of injectable insulin or a stable glucagon presentation; the
success of our formulation development work with insulin analog-based
formulations of a proprietary injectable insulin and a stable glucagon
presentation; our ability to secure approval from the FDA for our product
candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic
Act; the progress, timing or success of our research, development and clinical
programs, including any resulting data analyses; our ability to develop and
commercialize a proprietary formulation of injectable insulin that may be
associated with less injection site discomfort than Linjeta™ (formerly
referred to as VIAject^®), which is the subject of a complete response letter
we received from the FDA; our ability to enter into collaboration arrangements
for the commercialization of our product candidates and the success or failure
of any such collaborations into which we enter, or our ability to
commercialize our product candidates ourselves; our ability to protect our
intellectual property and operate our business without infringing upon the
intellectual property rights of others; the degree of clinical utility of our
product candidates; the ability of our major suppliers to produce our products
in our final dosage form; our commercialization, marketing and manufacturing
capabilities and strategies; our ability to accurately estimate anticipated
operating losses, future revenues, capital requirements and our needs for
additional financing; and other factors identified in our most recent report
on Form 10-Q for the quarter ended June 30, 2013. The company disclaims any
obligation to update any forward-looking statements as a result of events
occurring after the date of this press release.


CONTACT: Seth D. Lewis, +1-646-378-2952
Press spacebar to pause and continue. Press esc to stop.